Ovarian Cancer Clinical Trials (May 2026): ~490 Recruiting Interventional Studies
Last updated: May 7, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- PARP inhibitors (63 trials): beyond maintenance — combinations, re-challenge, new-gen PARPi
- ADCs (48 trials): mirvetuximab soravtansine (FRα), T-DXd (HER2), raludotatug deruxtecan, sacituzumab tirumotecan, BL-B01D1
- Checkpoint immunotherapy (50 trials): combinations to overcome platinum-resistant disease
- Folate receptor-targeted therapies, HIPEC, and MEK inhibitors for low-grade serous
Already approved: Olaparib, niraparib, rucaparib (PARP), bevacizumab, mirvetuximab soravtansine (FRα+ platinum-resistant)
Recruiting Trials by Treatment Setting
First-Line Maintenance (After Platinum Response)
PARP inhibitors ± bevacizumab are standard maintenance. Trials test new combinations and non-HRD strategies:
- NCT07472140 - PARP inhibitor ± angiogenesis inhibitor in HRD-positive primary ovarian cancer (Phase 3)
- NCT06580314 - Olaparib for 1 vs 2 years ± Bevacizumab (Phase 3)
- NCT06819007 - DESTINY-Ovarian01: T-DXd + Bevacizumab vs Bevacizumab maintenance in HER2-expressing (Phase 3)
- NCT07318558 - Sacituzumab Tirumotecan (MK-2870) in non-HRD positive advanced ovarian cancer (Phase 3)
Platinum-Sensitive Recurrence
- NCT07225270 - Rina-S (ADC) + SOC vs SOC for maintenance after 2L platinum-based chemo (Phase 3)
- NCT06824467 - Sacituzumab Tirumotecan (MK-2870) maintenance vs SOC in platinum-sensitive recurrence (Phase 3)
- NCT07213804 - Sofetabart Mipitecan (ADC) in platinum-sensitive ovarian cancer (Phase 3, Part B)
- NCT05009082 - Niraparib vs Niraparib + Bevacizumab after platinum/taxane chemo (Phase 3)
- NCT05255471 - MITO 35B: Olaparib beyond progression vs platinum chemo after secondary cytoreduction (Phase 3)
Platinum-Resistant / Refractory
Major unmet need. ADCs and novel agents are transforming this space:
- ADCs:
- NCT07218809 - AZD5335 vs Mirvetuximab (FRα-high) and AZD5335 vs Chemo (FRα-low) in platinum-resistant (Phase 3)
- NCT06161025 - Raludotatug Deruxtecan (R-DXd) in platinum-resistant high-grade ovarian cancer (Phase 3)
- NCT06834672 - IBI354 vs Chemo in platinum-resistant ovarian cancer (Phase 3)
- NCT06394492 - SHR-A1921 in platinum-resistant recurrent EOC (Phase 3)
- NCT06828354 - SHR-A1811 (T-DXd analog) in ovarian cancer (Phase 3)
- NCT06994195 - BL-B01D1 (EGFR×HER3 bispecific ADC) vs Chemo in platinum-resistant (Phase 3)
- Novel agents:
- NCT07214779 - INCB123667 vs Chemo in platinum-resistant with Cyclin E1 overexpression (Phase 3)
- NCT05281471 - OnPrime: Olvi-Vec (oncolytic virus) + platinum-doublet + bevacizumab vs Chemo + Bevacizumab (Phase 3)
- NCT04921527 - Chiauranib + weekly paclitaxel in platinum-resistant recurrence (Phase 3)
Surgery & Perioperative
- NCT04575935 - LANCE: Minimally invasive surgery after NACT for stage IIIC-IV (Phase 3)
- NCT05827523 - FOCUS: Interval cytoreductive surgery ± HIPEC (Phase 3)
- NCT06915025 - IMNN-001 + standard NACT and adjuvant chemo in newly diagnosed advanced EOC (Phase 3)
Specific Histologies
- Low-grade serous:
- NCT06072781 - Avutometinib (MEKi) + Defactinib (FAKi) in recurrent LGSOC (Phase 3)
- NCT05601700 - LEPRE: Letrozole for ER/PR-positive LGSOC (Phase 3)
- Early-stage:
- NCT04063527 - Stage I ovarian cancer after surgery (Phase 3)
Novel Approaches
- Next-gen ADCs: Raludotatug deruxtecan (CLN-619, FRα-targeted), sofetabart mipitecan, IBI354, SHR-A1921 — multiple new ADCs racing to improve on mirvetuximab
- Non-HRD maintenance: Sacituzumab tirumotecan, T-DXd — extending maintenance beyond BRCA/HRD patients
- Cyclin E1 targeting: INCB123667 for platinum-resistant ovarian cancer with CCNE1 amplification — biomarker-selected approach
- Oncolytic virus: Olvi-Vec combined with platinum chemotherapy for platinum-resistant disease
- Personalized vaccines: NCT06341907 - MRD + personalized vaccine for recurrence prevention after EOC surgery
Frequently Asked Questions
How do I find ovarian cancer clinical trials?
Paste your medical summary into ClinTrialFinder to get AI-matched ovarian cancer trials in minutes. The tool considers your BRCA status, HRD score, folate receptor alpha (FRα) expression, histology (high-grade serous, clear cell, low-grade serous, endometrioid), platinum sensitivity, and prior treatments.
What ovarian cancer trials are currently recruiting?
There are roughly 490 recruiting interventional trials for ovarian cancer in May 2026, including PARP inhibitors, next-generation ADCs (mirvetuximab soravtansine, raludotatug deruxtecan, sacituzumab tirumotecan, AZD5335, IBI354), checkpoint immunotherapy combinations, and novel agents for platinum-resistant disease including folate-receptor-targeted therapies, bispecific antibodies, and Cyclin E1 inhibitors.
Find Ovarian Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your BRCA/HRD status, histology, and treatment history.
Find Matching Trials
